Recital 46, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…

In forcesince 16 Apr 2014

In order to ensure subject safety and the reliability and robustness of data from clinical trials, it is appropriate to provide that there should be arrangements for traceability, storage, return and destruction of investigational medicinal products, depending on the nature of the clinical trial. For the same reasons, there should also be such arrangements for unauthorised auxiliary medicinal products.